Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18451027 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Zhu J, Blenis J, Yuan J (2008) Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 105, 6584-9 18451027
Download Sites

S145-p - Mad1 (human)
Orthologous residues
Mad1 (human): S145‑p, Mad1 (mouse): S144‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical), MCF-10A (breast cell), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE p70S6K (human)
KINASE p90RSK (human)
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6K (human) siRNA inhibition of enzyme, transfection of dominant-negative enzyme, phospho-antibody, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, modification site within consensus motif, inhibition of upstream enzyme, transfection of constitutively active enzyme
KINASE p90RSK (human) siRNA inhibition of enzyme, transfection of dominant-negative enzyme, phospho-antibody, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, modification site within consensus motif
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 serum no effect upon treatment-induced increase
PD98059 serum no effect upon treatment-induced increase
LY294002, PD98059 serum inhibit treatment-induced increase
rapamycin, PD98059 serum inhibit treatment-induced increase
serum Akt1 (human) inhibit treatment-induced increase dominant negative Akt1
serum p70S6K (human) inhibit treatment-induced increase dominant negative p70S6K
serum p90RSK (human) inhibit treatment-induced increase dominant negative p90RSK
siRNA serum p70S6K (human) no effect upon treatment-induced increase
siRNA serum p90RSK (human) no effect upon treatment-induced increase
siRNA serum p70S6K (human), p90RSK (human) inhibit treatment-induced increase
insulin increase
LY294002 insulin no effect upon treatment-induced increase
PD98059 insulin no effect upon treatment-induced increase
LY294002, PD98059 insulin inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  protein degradation
 Effect of modification (process):  cell growth, altered, transcription, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.